CRMP-2 Peptide Mediated Decrease of High and Low Voltage-Activated Calcium Channels, Attenuation of Nociceptor Excitability, and Anti-Nociception in a Model of AIDS Therapy-Induced Painful Peripheral Neuropathy

Abstract

Collectively, these results establish TAT-CBD3A6K as a peptide therapeutic with greater efficacy in an AIDS therapy-induced model of peripheral neuropathy than its parent peptide, TAT-CBD3. Structural modifications of the CBD3 scaffold peptide may result in peptides with selectivity against a particular subset of voltage-gated calcium channels resulting in a multipharmacology of action on the target.